Evidence demands action: An invitation to share the burden of proof

We welcome critical engagement with our study, "Dravet Syndrome: From Neurodevelopmental to Neurodegenerative Disease?" 1 and appreciate the opportunity to clarify our findings, strengthen our interpretations, and reassert their clinical importance. 1 The critiques raised (Sisodiya et al., 2025) underscore the importance of epistemological rigor and conceptual precision, which we support. 2 Yet, we must assert that our findings are robust, significant, and demand thoughtful reconsideration of current assumptions about the adult phenotype of Dravet syndrome (DS). | CONCEPTUAL FRAMING: NOT PREMATURE, BUT NECESSARYTerminological accuracy must not come at the expense of timely scientific inquiry.DS was once called "severe myoclonic epilepsy of infancy," a term that did not encompass the full clinical spectrum.Today, DS is classified as a developmental and epileptic encephalopathy (DEE), but this classification does not preclude the emergence of neurodegenerative processes later in life.